CDXC
vs
S&P 500
CDXC
S&P 500
Over the past 12 months, CDXC has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +30% growth.
Stocks Performance
CDXC vs S&P 500
Performance Gap
CDXC vs S&P 500
Performance By Year
CDXC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Chromadex Corp
Glance View
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 115 full-time employees. The company went IPO on 2007-06-25. NAD+ is a coenzyme and a regulator of cellular metabolism. The company operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.
